Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcía-Layana, A
dc.contributor.authorGarcía Arumí, José
dc.contributor.authorFigueroa, Marta
dc.contributor.authorArias, Luis
dc.contributor.authorRuíz-Moreno, J. M.
dc.contributor.authorMonclús-Arbona, L.
dc.date.accessioned2020-09-07T11:07:38Z
dc.date.available2020-09-07T11:07:38Z
dc.date.issued2019-09-30
dc.identifier.citationGarcía-Layana A, García-Arumí J, Figueroa MS, Arias Barquet L, Ruíz-Moreno JM, Monclús-Arbona L, et al. Management of wet age-related macular degeneration in Spain: challenges for treat and extend implementation in routine clinical practice. J Ophthalmol. 2019 Sep 30;2019:9821509.
dc.identifier.issn2090-004X
dc.identifier.urihttp://hdl.handle.net/11351/5220
dc.descriptionAge-related macular degeneration; Ophthalmology services; Anti-VEGF
dc.description.abstractPurpose. To ascertain wet AMD (wAMD) management patterns in Spain. Methods. A two-round Delphi study conducted through a questionnaire-based survey designed from literature review and validated by an independent Steering Committee. Results. Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a median time per visit of 15 minutes. Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and extend (T&E) dosing strategy is considered as optimal for wAMD management (78% of the panelists), the main routine healthcare limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined “flexible” strategies, based on T&E and pro-re-nata (PRN) protocols. Conclusion. Proactive treatment patterns (T&E) are the preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.
dc.language.isoeng
dc.publisherHindawi
dc.relation.ispartofseriesJournal of Ophthalmology;2019
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectDegeneració macular
dc.subjectProtocols clínics
dc.subjectEquips d'especialistes - Espanya
dc.subject.meshWet Macular Degeneration
dc.subject.meshDelphi Technique
dc.subject.meshClinical Protocols
dc.subject.meshSpain
dc.titleManagement of wet age-related macular degeneration in Spain: challenges for treat and extend implementation in routine clinical practice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1155/2019/9821509
dc.subject.decsdegeneración macular exudativa
dc.subject.decstécnica Delfos
dc.subject.decsprotocolos clínicos
dc.subject.decsEspaña
dc.relation.publishversionhttps://www.hindawi.com/journals/joph/2019/9821509/
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[García-Layana A] Clínica Universidad de Navarra, Pamplona, Spain. [García-Arumí J] Servei d’ Oftalmologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Figueroa MS] Vissum Madrid, Madrid, Spain. [Arias Barquet L] Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain. [Ruíz-Moreno JM] Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. [Monclús-Arbona L] Bayer Hispania, S.L., Sant Joan Despí, Spain
dc.identifier.pmid31662900
dc.identifier.wos000492292900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record